Palvella Therapeutics, Inc. has announced a key milestone in the development of therapies for rare genetic skin diseases: the completion of enrollment in its Phase 2 TOIVA trial of QTORIN™…
In our third installment from our series of reports provided by our partner TREND Community, we are bringing you several reports that analyze the effects of sleep disorders. This week…
Pfizer has announced breakthrough Phase 3 results for HYMPAVZI™ (marstacimab), a once-weekly subcutaneous therapy that could redefine care for people with hemophilia A or B who have developed inhibitors, as…
In our third installment from our series of reports provided by our partner TREND Community, we are bringing you several reports that analyze the effects of sleep disorders. This week…
A new RNA-based drug from Regeneron Pharmaceuticals and Alnylam Pharmaceuticals has shown positive results in a late-stage clinical trial for generalized myasthenia gravis (gMG), a rare, chronic autoimmune disease that…
In our third installment from our series of reports provided by our partner TREND Community, we are going to be focusing on a different condition over four weeks. This week…
A new study recently published in the European journal of Preventive Cardiology and reported by Medical News Today, noted that individuals who added extra steps plus reasonable speed to their…
AbbVie, a global biopharmaceutical leader, has reported disappointing results from a phase 2 clinical trial evaluating its interleukin-1 (IL-1) targeting drug, ABBV-668, as a monotherapy for patients with moderate to…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
